Cardiovascular and diabetes outcomes after metabolic bariatric surgery versus obesity management medications: nationwide overlap-weighted cohort study of 379 858 patients
British Journal of Surgery · 31.10.2026 · 113 (11)
DOI: 10.1093/bjs/znag139 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift British Journal of Surgery, online erschienen am 03.11.2026. Verfasst von Andrew P Gillikin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Virginia Health System, Charlottesville, Virginia, USA. Hauptthemen laut MEDLINE: Bariatric Surgery, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Obesity. Die Arbeit nennt 28 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Metabolic bariatric surgery (MBS) and incretin-based therapy (IBT) are effective treatments for obesity and type 2 diabetes (T2D). However, their comparative effectiveness in current practice remains incompletely defined.
Methods
Adults aged ≥18 years with obesity and T2D who underwent MBS or initiated obesity management medications (OMMs) were identified. The median follow-up was 4.9 (interquartile range (i.q.r.) 3.6–6.7) years for MBS and 4.3 (i.q.r. 3.4–5.8) years for IBT. Overlap weighting balanced baseline covariates between groups. Five-year outcomes included nephropathy, retinopathy, major adverse cardiovascular events (MACE), and all-cause mortality. One-year outcomes included percentage total weight loss (%TWL) and rates of haemoglobin A1c (HbA1c) <6.5%.
Results
In total, 379 858 adults met the inclusion criteria (32 401 underwent MBS and 347 457 initiated OMMs). After overlap weighting, baseline covariates were well balanced. Compared with OMMs, MBS was associated with lower 5-year cumulative incidences of nephropathy (4.5% versus 8.3%; −3.8% points; HR 0.55 (95% c.i. 0.52 to 0.60)), retinopathy (3.6% versus 7.4%; −3.8% points; HR 0.60 (95% c.i. 0.55 to 0.65)), MACE (6.1% versus 8.1%; −2.0% points; HR 0.78 (95% c.i. 0.73 to 0.84)), and all-cause mortality (2.1% versus 3.7%; −1.6% points; HR 0.61 (95% c.i. 0.55 to 0.69)). At 1 year, the mean %TWL was greater after MBS (25.4% (95% c.i. 25.3% to 25.5%)) than after OMMs (6.4% (95% c.i. 6.3% to 6.5%)). Among patients with baseline HbA1c ≥6.5%, the proportion achieving HbA1c <6.5% at 1 year was higher after MBS (76.7% (95% c.i. 75.3% to 78.0%)) than after OMMs (47.2% (95% c.i. 46.2% to 48.1%); P < 0.001). Findings were consistent across agent-stratified, competing-risk, landmark, and no-censoring sensitivity analyses.
Conclusion
Among adults with obesity and T2D, MBS was associated with greater %TWL, higher glycaemic normalization, and lower 5-year risks of nephropathy, retinopathy, MACE, and all-cause mortality compared with real-world initiation of OMMs among patients in clinical equipoise, supporting the role of MBS as a durable therapy in multimodal obesity management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Surgery, University of Virginia Health System, Charlottesville, Virginia, USA.
- Department of Surgery, Mass General Brigham, Boston, Massachusetts, USA.
ORCID-Profile: Abdelrahman A Nimeri
Zitieren
APA
Gillikin, A. P., Rabinovich, E. P., Nimeri, A. A., Tavakkoli, A., & Shin, T. H. (2026). Cardiovascular and diabetes outcomes after metabolic bariatric surgery versus obesity management medications: nationwide overlap-weighted cohort study of 379 858 patients. British Journal of Surgery, 113(11). https://doi.org/10.1093/bjs/znag139
Vancouver
Gillikin AP, Rabinovich EP, Nimeri AA, Tavakkoli A, Shin TH. Cardiovascular and diabetes outcomes after metabolic bariatric surgery versus obesity management medications: nationwide overlap-weighted cohort study of 379 858 patients. British Journal of Surgery. 2026;113(11). doi:10.1093/bjs/znag139
BibTeX
@article{Gillikin2026,
author = {Gillikin, Andrew P and Rabinovich, Emily P and Nimeri, Abdelrahman A and Tavakkoli, Ali and Shin, Thomas H},
title = {Cardiovascular and diabetes outcomes after metabolic bariatric surgery versus obesity management medications: nationwide overlap-weighted cohort study of 379 858 patients},
journal = {British Journal of Surgery},
year = {2026},
volume = {113},
number = {11},
doi = {10.1093/bjs/znag139}
}
EUVIMED